Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2012

View Archived Issues

SIRT1 activation investigated in models of obesity

Novel data reported on GKM-001 in diabetes and obesity

Phase I results encourage continued clinical evaluation of PEGylated C-peptide

First-in-human data disclosed on gene-modified T cells to facilitate stem cell transplants

Roche presents novel LRRK2 inhibitors

Bristol-Myers Squibb patents novel inhibitors of CYP17

Novel diagnostics disclosed by Janssen Pharmaceuticals

Merck & Co. reports new CGRP receptor antagonists

New PI3K inhibitors developed in U.S.

Synta Pharmaceuticals prepares new IL-2/CRAC-targeted products

Pharmanest launches phase II study of SHACT

Eltoprazine study in Parkinson's disease meets primary objective

Summit achieves milestone in development of SMT-C1100

Novel dipeptidyl peptidase IV inhibitor shows promise in diabetes/obesity models

Combination therapy shows surprising synergistic efficacy in Batten disease model

VaxInnate begins phase I H5N1 vaccine study

ImaginAb and BZL Biologics expand collaboration

Invega Sustenna formulation enters phase III trials

Greer reports data from phase III sublingual immunotherapy trial

Proof-of-concept study begins for Ampyra

Cempra starts phase II trial in gonococcal infections

Lead Tokai product receives FDA fast track status

Two first-in-class PolyMedix products receive approved generic names

Jazz Pharmaceuticals completes acquisition

FDA grants fast track status to synthetic ectodysplasin-A

Enrollment under way in NX-1207 trial in low-grade localized prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...